Logo image of CASI

CASI PHARMACEUTICALS INC (CASI) Stock Price, Quote, News and Overview

NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD

1.86  +0.01 (+0.67%)

CASI Quote, Performance and Key Statistics

CASI PHARMACEUTICALS INC

NASDAQ:CASI (6/3/2025, 4:30:02 PM)

1.86

+0.01 (+0.67%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High7.67
52 Week Low1.63
Market Cap28.81M
Shares15.49M
Float7.74M
Yearly Dividend0.05
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-14 2025-08-14
IPO08-23 2021-08-23


CASI short term performance overview.The bars show the price performance of CASI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

CASI long term performance overview.The bars show the price performance of CASI in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of CASI is 1.86 USD. In the past month the price decreased by -2.87%. In the past year, price decreased by -46.4%.

CASI PHARMACEUTICALS INC / CASI Daily stock chart

CASI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.23 330.76B
AMGN AMGEN INC 13.95 155.70B
GILD GILEAD SCIENCES INC 14.13 136.00B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.66B
REGN REGENERON PHARMACEUTICALS 11.01 52.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.61B
ARGX ARGENX SE - ADR 100.28 35.21B
BNTX BIONTECH SE-ADR N/A 27.80B
ONC BEONE MEDICINES LTD-ADR 6.45 27.21B
NTRA NATERA INC N/A 21.87B
BIIB BIOGEN INC 8.33 19.32B
SMMT SUMMIT THERAPEUTICS INC N/A 15.31B

About CASI

Company Profile

CASI logo image CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Company Info

CASI PHARMACEUTICALS INC

1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District

Beijing BEIJING 20850 CN

CEO: Wei-Wu He

Employees: 233

CASI Company Website

CASI Investor Relations

Phone: 861065618789

CASI PHARMACEUTICALS INC / CASI FAQ

What is the stock price of CASI PHARMACEUTICALS INC today?

The current stock price of CASI is 1.86 USD. The price increased by 0.67% in the last trading session.


What is the ticker symbol for CASI PHARMACEUTICALS INC stock?

The exchange symbol of CASI PHARMACEUTICALS INC is CASI and it is listed on the Nasdaq exchange.


On which exchange is CASI stock listed?

CASI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CASI PHARMACEUTICALS INC stock?

7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 119.35% is expected in the next year compared to the current price of 1.86. Check the CASI PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CASI PHARMACEUTICALS INC worth?

CASI PHARMACEUTICALS INC (CASI) has a market capitalization of 28.81M USD. This makes CASI a Nano Cap stock.


How many employees does CASI PHARMACEUTICALS INC have?

CASI PHARMACEUTICALS INC (CASI) currently has 233 employees.


What are the support and resistance levels for CASI PHARMACEUTICALS INC (CASI) stock?

CASI PHARMACEUTICALS INC (CASI) has a resistance level at 1.95. Check the full technical report for a detailed analysis of CASI support and resistance levels.


Is CASI PHARMACEUTICALS INC (CASI) expected to grow?

The Revenue of CASI PHARMACEUTICALS INC (CASI) is expected to decline by -5.03% in the next year. Check the estimates tab for more information on the CASI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CASI PHARMACEUTICALS INC (CASI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CASI PHARMACEUTICALS INC (CASI) stock pay dividends?

CASI does not pay a dividend.


When does CASI PHARMACEUTICALS INC (CASI) report earnings?

CASI PHARMACEUTICALS INC (CASI) will report earnings on 2025-08-14.


What is the Price/Earnings (PE) ratio of CASI PHARMACEUTICALS INC (CASI)?

CASI PHARMACEUTICALS INC (CASI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.51).


What is the Short Interest ratio of CASI PHARMACEUTICALS INC (CASI) stock?

The outstanding short interest for CASI PHARMACEUTICALS INC (CASI) is 0.22% of its float. Check the ownership tab for more information on the CASI short interest.


CASI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CASI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CASI. CASI has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CASI Financial Highlights

Over the last trailing twelve months CASI reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS decreased by -10.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -99.16%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%2.82%
Sales Q2Q%83.04%
EPS 1Y (TTM)-10.09%
Revenue 1Y (TTM)8.39%

CASI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CASI. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 19.14% and a revenue growth -5.03% for CASI


Ownership
Inst Owners26.68%
Ins Owners23.58%
Short Float %0.22%
Short Ratio1.72
Analysts
Analysts82.86
Price Target4.08 (119.35%)
EPS Next Y19.14%
Revenue Next Year-5.03%